Vivoryon Therapeutics N.V. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for [Alzheimer's disease](/diseases/alzheimers-disease) and other neurodegenerative conditions. Headquartered in Amsterdam, Netherlands, with operations in Munich, Germany, Vivoryon is pioneering a novel approach targeting glutaminyl cyclase (QC) inhibition to prevent the formation of toxic [amyloid-beta](/proteins/amyloid-beta) oligomers[@vivoryon].
The company was founded in 2006 as a spin-off from the University of Munich (LMU), leveraging over a decade of academic research on the role of glutaminyl cyclase in neurodegenerative disease. Vivoryon's lead candidate, varoglutamstat (formerly PQ912), represents one of the few disease-modifying approaches in clinical development that targets a specific toxic amyloid-beta species rather than amyloid plaque formation broadly.
| Attribute | Details |
|-----------|---------|
| Headquarters | Amsterdam, Netherlands (legal) |
| Operations | Munich, Germany |
| Founded | 2006 |
| Stock Exchange | Euronext Amsterdam |
| Ticker | VVY |
| Employees | ~50 |
| Market Cap | ~€50-100 million |
Vivoryon Therapeutics N.V. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for [Alzheimer's disease](/diseases/alzheimers-disease) and other neurodegenerative conditions. Headquartered in Amsterdam, Netherlands, with operations in Munich, Germany, Vivoryon is pioneering a novel approach targeting glutaminyl cyclase (QC) inhibition to prevent the formation of toxic [amyloid-beta](/proteins/amyloid-beta) oligomers[@vivoryon].
The company was founded in 2006 as a spin-off from the University of Munich (LMU), leveraging over a decade of academic research on the role of glutaminyl cyclase in neurodegenerative disease. Vivoryon's lead candidate, varoglutamstat (formerly PQ912), represents one of the few disease-modifying approaches in clinical development that targets a specific toxic amyloid-beta species rather than amyloid plaque formation broadly.
| Attribute | Details |
|-----------|---------|
| Headquarters | Amsterdam, Netherlands (legal) |
| Operations | Munich, Germany |
| Founded | 2006 |
| Stock Exchange | Euronext Amsterdam |
| Ticker | VVY |
| Employees | ~50 |
| Market Cap | ~€50-100 million |
Vivoryon's therapeutic approach is based on the inhibition of glutaminyl cyclase (QC), an enzyme that catalyzes the N-terminal cyclization of glutamate residues in certain proteins, including [amyloid-beta](/proteins/amyloid-beta). This post-translational modification produces pyroglutamate-modified amyloid-beta (pGlu-Aβ or AβpE3-x), a particularly neurotoxic variant of the amyloid-beta peptide[@schilling2012].
Key characteristics of pGlu-Aβ:
Varoglutamstat works by inhibiting the glutaminyl cyclase enzyme, thereby preventing the formation of pGlu-Aβ species. This mechanism is distinct from other approaches in the AD pipeline:
Therapeutic benefits of QC inhibition:
| Year | Milestone |
|------|-----------|
| 2006 | Company founded as LMU spin-off |
| 2015 | Varoglutamstat enters Phase 1 clinical trials |
| 2018 | Phase 2a SAPIR trial initiated |
| 2021 | Phase 2b VIVIAD trial initiated |
| 2024 | Phase 2b ongoing, multiple publications |
Phase 1 clinical trials demonstrated several important findings[@poirier2020]:
The SAPIR trial was a randomized, double-blind, placebo-controlled study evaluating varoglutamstat in patients with early Alzheimer's disease. Key findings included:
Efficacy signals:
The ongoing Phase 2b VIVIAD study is evaluating varoglutamstat in a larger patient population with early Alzheimer's disease:
| Program | Indication | Stage | Notes |
|---------|------------|-------|-------|
| Varoglutamstat (PQ912) | Early AD | Phase 2b | Lead candidate |
| PQ1565 | Inflammatory disease | Preclinical | QC inhibition |
| PQ1106 | Neurodegeneration | Discovery | Next-generation QC inhibitor |
| QC inhibitor platform | Various | Discovery | Multiple programs |
Varoglutamstat occupies a unique position in the AD therapeutic landscape:
| Approach | Target | Company | Stage | Mechanism |
|----------|--------|---------|-------|-----------|
| Varoglutamstat | pGlu-Aβ | Vivoryon | Phase 2b | QC inhibitor |
| Lecanemab | Aβ plaques | Eisai/Biogen | Approved | Anti-amyloid mAb |
| Donanemab | N3pG Aβ | Eli Lilly | Approved | Anti-amyloid mAb |
| Semaglintide | Aβ aggregation | Eli Lilly | Phase 2 | GLP-1 analog |
| Blarcamesine | Sigma-1 agonist | Anavex | Phase 2/3 | Neuroprotective |
The amyloid cascade hypothesis, originally proposed by Hardy and Higgins in 1992, posits that accumulation of amyloid-beta peptide in the brain is the primary event in Alzheimer's disease that triggers downstream pathological processes including tau phosphorylation, neuroinflammation, synaptic loss, and neuronal death[@selkoe2001]. While this hypothesis has been foundational to AD research, the approval of lecanemab and donanemab has validated the amyloid-targeting approach while also revealing its limitations.
Modern understanding has refined the hypothesis to focus on soluble oligomeric species rather than insoluble plaques[@haass2007]. Amyloid-beta oligomers are now recognized as the most toxic species, causing synaptic dysfunction and cognitive decline even before substantial plaque deposition occurs[@benilova2010]. This understanding has shifted drug development toward targeting specific toxic Aβ species rather than plaque removal broadly.
pGlu-Aβ represents a particularly aggregation-prone and neurotoxic variant of the amyloid-beta peptide. The N-terminal glutamination catalyzed by glutaminyl cyclase converts Aβ1-40 and Aβ1-42 into pGlu-Aβ3-40/42, which exhibit several pathogenic properties[@schilling2012]:
Aggregation kinetics: pGlu-Aβ3-42 shows accelerated oligomerization compared to unmodified Aβ1-42, forming stable low-molecular-weight oligomers within hours rather than days. These oligomers are resistant to dissociation and serve as templates for further aggregation.
Neurotoxicity: In vitro studies demonstrate that pGlu-Aβ oligomers are more potent inducers of oxidative stress, mitochondrial dysfunction, and synaptic damage than equivalent concentrations of unmodified Aβ. The toxic mechanism involves disruption of calcium homeostasis, activation of apoptotic pathways, and impairment of synaptic plasticity[@moreno2019].
Seeding activity: pGlu-Aβ acts as an efficient "seed" that catalyzes the aggregation of normal Aβ species. This prion-like property means that even small amounts of pGlu-Aβ can accelerate the formation of toxic oligomers throughout the brain[@wanker2014].
Early appearance: Post-mortem studies show elevated pGlu-Aβ in the brains of individuals with mild cognitive impairment and early AD, suggesting these species appear early in disease pathogenesis. The presence of pGlu-Aβ in Down syndrome patients prior to classic AD pathology indicates these modified peptides may be among the earliest markers of amyloid pathology.
Glutaminyl cyclase (QC) catalyzes the conversion of N-terminal glutamine to pyroglutamate in various substrates, including amyloid-beta. The enzyme exists in two forms[@sykes2011]:
The development of varoglutamstat (PQ912) followed a systematic drug discovery process[@sykes2011]:
The binding mode of PQ912 to secretory glutaminyl cyclase has been characterized through crystallography and computational modeling[@chandran2021], confirming the compound binds to the active site and stabilizes the enzyme in an inactive conformation.
Preclinical studies suggest QC inhibition may synergize with other therapeutic approaches. Combination of varoglutamstat with anti-Aβ monoclonal antibodies shows additive effects on amyloid pathology in transgenic mouse models[@hoffmann2021], providing a rationale for potential combination therapy in clinical development.
Varoglutamstat is being developed for:
Vivoryon is employing a comprehensive biomarker approach:
The VIVIAD trial design reflects lessons learned from previous AD clinical trials[@vijverberg2021]:
The Alzheimer's disease market represents one of the largest unmet needs in pharmaceutical development:
| Approach | Target | Company | Stage | Mechanism |
|----------|--------|--------|-------|-----------|
| Varoglutamstat | pGlu-Aβ | Vivoryon | Phase 2b | QC inhibitor |
| Lecanemab | Aβ plaques | Eisai/Biogen | Approved | Anti-amyloid mAb |
| Donanemab | N3pG Aβ | Eli Lilly | Approved | Anti-amyloid mAb |
| Semaglintide | Aβ aggregation | Eli Lilly | Phase 2 | GLP-1 analog |
| Blarcamesine | Sigma-1 agonist | Anavex | Phase 2/3 | Neuroprotective |
Varoglutamstat's oral delivery and novel mechanism position it differently from approved monoclonal antibody therapies:
Vivoryon was founded in 2006 as a spin-off from the University of Munich (LMU). The company initially focused on developing QC inhibitors for various indications. In 2017, Vivoryon merged with the German company Vivoryon Therapeutics AG to strengthen its pipeline. The company went public on the Euronext Amsterdam stock exchange in 2019.
In 2024, Vivoryon completed an acquisition to consolidate its position and focus resources on the varoglutamstat program.
Vivoryon has collaborated with:
Varoglutamstat is being developed for:
Vivoryon is employing a comprehensive biomarker approach:
The Alzheimer's disease market represents one of the largest unmet needs in pharmaceutical development: